KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Payables (2016 - 2025)

Alnylam Pharmaceuticals' Payables history spans 17 years, with the latest figure at $115.7 million for Q4 2025.

  • For Q4 2025, Payables rose 30.88% year-over-year to $115.7 million; the TTM value through Dec 2025 reached $115.7 million, up 30.88%, while the annual FY2025 figure was $115.7 million, 30.88% up from the prior year.
  • Payables reached $115.7 million in Q4 2025 per ALNY's latest filing, down from $117.6 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $117.6 million in Q3 2025 to a low of $40.0 million in Q3 2021.
  • Average Payables over 5 years is $72.7 million, with a median of $72.1 million recorded in 2021.
  • Peak YoY movement for Payables: soared 103.17% in 2021, then plummeted 43.4% in 2023.
  • A 5-year view of Payables shows it stood at $73.4 million in 2021, then surged by 33.6% to $98.1 million in 2022, then plummeted by 43.4% to $55.5 million in 2023, then surged by 59.25% to $88.4 million in 2024, then surged by 30.88% to $115.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Payables are $115.7 million (Q4 2025), $117.6 million (Q3 2025), and $102.4 million (Q2 2025).